ASSESSMENT OF GUT MICROBIOTA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A COMPREHENSIVE ANALYSIS
DOI:
https://doi.org/10.55640/Keywords:
irritable bowel syndrome, gut microbiota, dysbiosis, 16S rRNA sequencing, metagenomics, short-chain fatty acids, gut-brain axis, probiotics.Abstract
This article presents a comprehensive assessment of gut microbiota composition and diversity in patients with irritable bowel syndrome (IBS). IBS is a common functional gastrointestinal disorder affecting 10-15% of the global population, with emerging evidence implicating gut microbiota dysbiosis in its pathophysiology. A case-control study of 120 IBS patients (40 IBS-D, 40 IBS-C, 40 IBS-M) and 40 healthy controls was conducted, employing 16S rRNA gene sequencing, metagenomic analysis, and metabolomic profiling. Comprehensive clinical assessment included Rome IV diagnostic criteria, symptom severity scoring, and quality of life evaluation. Results revealed significant microbiota alterations in IBS patients, including reduced alpha diversity (Shannon index 3.2±0.6 vs 4.1±0.5 in controls, p<0.001), decreased Firmicutes/Bacteroidetes ratio (1.8±0.4 vs 2.6±0.5, p<0.001), and reduced abundance of beneficial bacteria (Faecalibacterium prausnitzii, Bifidobacterium spp). IBS-D showed increased Enterobacteriaceae (12.4±3.2% vs 3.8±1.2%, p<0.001), while IBS-C demonstrated reduced Prevotella abundance. Metabolomic analysis identified altered short-chain fatty acid profiles and increased fecal calprotectin levels. The discussion emphasizes the gut-brain axis, immune modulation, and therapeutic implications including probiotics, prebiotics, fecal microbiota transplantation, and dietary interventions.
Downloads
References
1. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis // Clinical Gastroenterology and Hepatology. 2012. Vol. 10(7). P. 712-721. DOI: 10.1016/j.cgh.2012.02.029
2. Drossman D.A., Hasler W.L. Rome IV - functional GI disorders: disorders of gut-brain interaction // Gastroenterology. 2016. Vol. 150(6). P. 1257-1261. DOI: 10.1053/j.gastro.2016.03.035
3. Sender R., Fuchs S., Milo R. Revised estimates for the number of human and bacteria cells in the body // PLoS Biology. 2016. Vol. 14(8). P. e1002533. DOI: 10.1371/journal.pbio.1002533
4. Simrén M., Barbara G., Flint H.J., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report // Gut. 2013. Vol. 62(1). P. 159-176. DOI: 10.1136/gutjnl-2012-302167
5. Mayer E.A., Tillisch K., Gupta A. Gut/brain axis and the microbiota // Journal of Clinical Investigation. 2015. Vol. 125(3). P. 926-938. DOI: 10.1172/JCI76304
6. Cryan J.F., O'Mahony S.M. The microbiome-gut-brain axis: from bowel to behavior // Neurogastroenterology & Motility. 2011. Vol. 23(3). P. 187-192. DOI: 10.1111/j.1365-2982.2010.01664.x
7. Jeffery I.B., O'Toole P.W., Öhman L., et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota // Gut. 2012. Vol. 61(7). P. 997-1006. DOI: 10.1136/gutjnl-2011-301501
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
